Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Preeclampsia Screening Trial to Improve Outcomes (PRESTO)

10 de novembro de 2026 atualizado por: Suchitra Chandrasekaran, Emory University

Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy

The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.

The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.

Visão geral do estudo

Descrição detalhada

Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.

Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.

Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.

Tipo de estudo

Intervencional

Inscrição (Estimado)

1000

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Georgia
      • Decatur, Georgia, Estados Unidos, 30033
        • Emory Decatur Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Pregnant persons aged 18 years or older.
  • Singleton pregnancy.
  • Gestational age from 23 weeks 0 days through 33 weeks 6 days.
  • Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
  • Provision of signed informed consent (English- or Spanish-speaking).

Exclusion Criteria:

  • Enrollment in another therapeutic interventional trial with a primary outcome of HDP
  • Receipt of intravenous heparin during hospitalization.
  • Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
  • Prior study enrollment during the current pregnancy.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Blinded Test Results (Phase A)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units.

Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care.

Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

Outros nomes:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara
Experimental: Real Time Results (Phase B)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study.

During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

Outros nomes:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara

sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pregnancy latency
Prazo: At delivery (up to 40 weeks of gestation)

Time from admission to delivery

At delivery (up to 40 weeks of gestation)
Participants with maternal adverse outcomes
Prazo: From enrollment until post-natal discharge (on average 10 days post-delivery)

The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive.

From enrollment until post-natal discharge (on average 10 days post-delivery)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants who require hospital admission
Prazo: From enrollment up to 37 weeks of gestation

Number of participants who require hospital admission during study participation, collected form medical records.

From enrollment up to 37 weeks of gestation
Number of participants with indicated delivery within 14 days of presentation
Prazo: Up to 14 days from enrollment

Participants who require delivery within 14 days of presentation

Up to 14 days from enrollment
Number of participants who require transfer to tertiary care centers
Prazo: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)

Participants who require transfer to tertiary care centers as documented in the medical records.

From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
Number of participants who received antenatal corticosteroid administration
Prazo: Between 24 weeks and 34 weeks of gestation

Participants who receive antenatal corticosteroid administration as documented in the medical records.

Between 24 weeks and 34 weeks of gestation
Number of preterm births less than 37 weeks
Prazo: From enrollment up to 36 weeks and 6 days of pregnancy

Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods.

From enrollment up to 36 weeks and 6 days of pregnancy
Number of early preterm births
Prazo: From enrollment up to 31 weeks and 6 days of pregnancy

Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation.

From enrollment up to 31 weeks and 6 days of pregnancy
Composite Adverse Fetal/Neonatal Outcomes
Prazo: From maternal enrollment through 28 days after birth

Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups.

From maternal enrollment through 28 days after birth
Length of hospital admission (mother's) of stay,
Prazo: From admission until post-natal hospital discharge (on average 10 days post-delivery)

Length of hospital admission, extracted from medical records

From admission until post-natal hospital discharge (on average 10 days post-delivery)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Suchitra Chandrasekaran, MD, Emory University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de junho de 2028

Conclusão do estudo (Estimado)

1 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

14 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.

The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.

Prazo de Compartilhamento de IPD

No specific end date has been established.

Critérios de acesso de compartilhamento IPD

Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever